Ipca Laboratories Ratios

Ipca Laboratories Ltd Ratios

The Ipca Laboratories Ltd Ratios page provides a complete fundamental analysis of Ipca Laboratories Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Ipca Laboratories Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Ipca Laboratories Ltd (NSE: IPCALAB, BSE: 524494) is currently trading at ₹1533.90, with a market capitalization of ₹378.03B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Ipca Laboratories Ltd remains a key stock for fundamental analysis using Ipca Laboratories Ltd Ratios.

Ipca Laboratories Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Ipca Laboratories Ltd P/E ratio currently stands at 51.63, making it one of the most tracked metrics in Ipca Laboratories Ltd Ratios.

Historically, the Ipca Laboratories Ltd P/E ratio has shown strong fluctuations:

• 2024: 51.63
• 2023: 57.39
• 2022: 43.62
• 2021: 30.45
• 2020: 42.28

The decline in Ipca Laboratories Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Ipca Laboratories Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 5.48.

Historical P/B trend:

• 2024: 5.48
• 2023: 4.96
• 2022: 3.52
• 2021: 4.93

Ipca Laboratories Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Ipca Laboratories Ltd P/S ratio currently stands at 4.30, an important part of Ipca Laboratories Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 4.30
• 2023: 4.13
• 2022: 3.32
• 2021: 4.67

The rising Ipca Laboratories Ltd P/S ratio indicates improved revenue valuation by investors.

Ipca Laboratories Ltd Price to Cash Flow Ratio (P/CF)

The Ipca Laboratories Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 29.87.

Historical Ipca Laboratories Ltd Price to Cash Flow Ratio:

• 2024: 29.87
• 2023: 35.15
• 2022: 25.06
• 2021: 30.45
• 2020: 43.61

The declining Ipca Laboratories Ltd Price to Cash Flow Ratio suggests improving cash flow strength.

Ipca Laboratories Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Ipca Laboratories Ltd EV currently stands at ₹397.84B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 397.84B
• 2023: 333.93B
• 2022: 199.25B
• 2021: 264.35B

Ipca Laboratories Ltd enterprise value shows long-term growth, reflecting expansion and market confidence.

EV/EBITDA Ratio

The Ipca Laboratories Ltd EV/EBITDA ratio is currently 23.08, a key metric in Ipca Laboratories Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 23.08
• 2023: 28.90
• 2022: 20.07
• 2021: 20.61

Stable Ipca Laboratories Ltd EV/EBITDA indicates balanced valuation.

Ipca Laboratories Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Ipca Laboratories Ltd D/E ratio is currently 0.20, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.20
• 2023: 0.23
• 2022: 0.25
• 2021: 0.15

Ipca Laboratories Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Ipca Laboratories Ltd ROE currently stands at 11.11%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 11.11
• 2023: 8.99
• 2022: 8.32
• 2021: 17.39

Ipca Laboratories Ltd maintains stable profitability levels.

Ipca Laboratories Ltd Ratios Analysis Summary

The Ipca Laboratories Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Ipca Laboratories Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Ipca Laboratories Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.